The data are positive but early-stage; watch for upcoming regulatory milestones (FDA filings for olverembatinib, Takeda option decision) and further readouts. Near-term stock price movement likely limited given historical weak reaction to pipeline updates.
Price Chart
Executive Summary
Ascentage Pharma presented positive clinical data for three key drug candidates at ASCO 2026, including first pediatric data for MDM2-p53 inhibitor alrizomadlin, updated olverembatinib results in CML-CP, and olverembatinib + blinatumomab in advanced Ph+ leukemias. The data are encouraging but preliminary, with no immediate financial impact.
Key Facts
- First dataset for alrizomadlin (APG-115) in pediatric solid tumors: ORR 23.5% in combination arm, 1 CR in monotherapy.
- Olverembatinib as second-line CML-CP: at cycle 24, CCyR 91.3%, MMR 60.9%, deepening over time.
- Olverembatinib + blinatumomab in CML-LBP/Ph+ BCP-ALL: 91% CR/CRi, 67% BCR::ABL1 negativity, 80% MRD negativity.
- All three studies were selected as rapid oral presentations at ASCO 2026; alrizomadlin included in China's SPARK Plan for pediatric solid tumors.
- No financial or revenue data included in the filing; all drugs remain investigational in the US.
Financial Impact
No financial figures provided; clinical data may support future regulatory filings and Takeda option exercise, but no near-term revenue impact.
Risk Factors
- Clinical data are preliminary and from small sample sizes; larger confirmatory trials needed.
- All candidates remain unapproved by the US FDA; regulatory risk persists.
- Historical stock price reactions to similar announcements have been negative on average.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063156 |
| Document: ea029289901ex99-2.htm | 0001213900-26-063156 |
| Document: ea029289901ex99-3.htm | 0001213900-26-063156 |
| Document: ea0292899-6k_ascentage.htm | 0001213900-26-063156 |
| Document: 0001213900-26-063156-index-headers.html | 0001213900-26-063156 |
| Document: 0001213900-26-063156-index.html | 0001213900-26-063156 |
| Document: 0001213900-26-063156.txt | 0001213900-26-063156 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $14.92 | awaiting T+1 | — | $15.43 (+3.38%) |
Oct 21, 2026 4d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $15.43 (+3.38%) |
Oct 15, 2026 11d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $15.43 (+5.00%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $15.43 (−0.36%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $15.43 (+10.94%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $15.43 (−8.48%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $15.43 (−8.21%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $15.43 (−18.34%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $15.43 (−16.03%) |
Jul 13, 2026 14w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $15.43 (−19.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers